A new eye-focused biotech is out of stealth, with plans to barrel toward PhII studies
A new biotech emerged from stealth and joined the Massachusetts biotech scene this morning, announcing its launch with a Series A for $10.5 million.
Aramis Biosciences, founded back in 2018, had its financing round led by Cambridge-based investors Safar Partners, alongside a strategic investment from an unnamed ophthalmic pharmaceutical company.
Funds from the financing will be used to advance Aramis’s pipeline, which comprises essentially its lead product candidate A197, a topical immunomodulatory agent licensed from Italian biotech Dompé farmaceutici. Aramis is prepped to take it through Phase II proof-of-concept studies for dry eye disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
